CPIG
RNTX

Chicago Partners Investment Group’s Rein Therapeutics RNTX Stock Holding History

Chicago Partners Investment Group’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.8K Hold
41,048
– – ﹤0.01% 1526
2026
Q1 		$77.2K Buy
41,048
+10,000
+32% +$12.4K ﹤0.01% 1404
2025
Q4 		$42.5K Hold
31,048
– – ﹤0.01% 1283
2025
Q3 		$41K Sell
31,048
-10,194
-25% -$12.9K ﹤0.01% 1202
2025
Q2 		$63.9K Buy
41,242
+5,330
+15% +$9.6K ﹤0.01% 1076
2025
Q1 		$58.5K Buy
+35,912
New +$75.4K ﹤0.01% 913

Other funds holding RNTX

SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
JWA
JFS Wealth Advisors Hermitage, Pennsylvania $2.01B AUM 21.74% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Chicago Partners Investment Group's RNTX Position: Q2 2026 in Review

Chicago Partners Investment Group held its Rein Therapeutics (RNTX) position steady in Q2 2026 at 41,048 shares worth $32.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1526.

Chicago Partners Investment Group first reported a position in RNTX in Q1 2025 and has held it in 6 quarters since. The position peaked at $77.2K in Q1 2026. 6 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Chicago Partners Investment Group held 41,048 shares of Rein Therapeutics worth $32.8K as of Q2 2026.
  • Chicago Partners Investment Group left its Rein Therapeutics share count unchanged in Q2 2026.
  • Rein Therapeutics made up ﹤0.01% of Chicago Partners Investment Group's portfolio in Q2 2026, its #1526 holding.
  • Chicago Partners Investment Group first reported a position in Rein Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Chicago Partners Investment Group's Rein Therapeutics position peaked at $77.2K in Q1 2026.
  • 6 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Chicago Partners Investment Group's 13F filing for Q2 2026, filed 30 Jul 2026.